Jakafi (ruxolitinib) is the first and only FDA-approved treatment for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea1.
Ruxolitinib (trade name Jakavi) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea.
- Brand Name - Jakavi
- Generic - Ruxolitinib
- Strength - 5 Mg, 15 Mg and 20 Mg
- Form - Tablets
- Packing - 56 Tablets
- Manufactured by - Novartis
Warning: Jakavi medicine out of the reach and sight of children and away from pets, never share your medicines with others, and use this medication only for the indication prescribed. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.
Attention Required: Jakavi medicine is a prescription drug and should be used under proper medical guidance and advice. Do not share the Jakavi medicine with others, since they may be suffering from a problem that is not effectively treated by this drug. If you have questions about the Jakavi drugs you are taking, check with your doctor / Medical adviser / Nurse / Hospital Institution / Health advisor or pharmacist.
Notice: The above information is an educational aid only. It is not intended as medical advice for individual conditions or treatments. Talk to your doctor, nurse or pharmacist before following any medical regimen to see if it is safe and effective for you.